{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:13:25Z","timestamp":1788776005386,"version":"build-2803163510"},"reference-count":185,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin","award":["WM-130\/S\/2025"],"award-info":[{"award-number":["WM-130\/S\/2025"]}]},{"name":"Pomeranian Medical University in Szczecin, Poland","award":["WM-130\/S\/2025"],"award-info":[{"award-number":["WM-130\/S\/2025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cardiovascular diseases (CVDs) are the leading cause of global mortality, with type 2 diabetes mellitus (T2DM) and obesity significantly increasing the risk of CVD. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4is) have gained attention for their potential cardioprotective effects. Therefore, this review aims to explore the molecular mechanisms underlying the cardiovascular benefits of these agents. A literature review was conducted searching PubMed databases from 1990 to January 2025, including research on the effects of GLP-1 RA and DPP-4i on cardiovascular health, specifically concerning atherosclerosis, coronary artery disease, vascular health, cardiac arrhythmias, myocardial infarction (MI), and heart failure, with a focus on the biochemical and molecular effects of these drugs. We analyzed 131 scientific publications, which indicate that GLP-1 RA and DPP-4i significantly reduce cardiovascular risk and major adverse cardiovascular events (MACEs), including atherosclerosis, myocardial infarction, and cardiac arrhythmias. These clinical outcomes are attributed to the mitigation of oxidative stress, inflammation, and endothelial dysfunction as well as improvement in mitochondrial function and lipid metabolism. GLP-1 RAs offer substantial cardiovascular benefits, making them valuable in managing T2DM and reducing CVD risk. Their integration into treatment regimens for CVD can reduce hospitalization rates, improve quality of life, and extend life expectancy. DPP-4is, while beneficial, are less effective in cardiovascular protection. Further research is needed to optimize therapeutic strategies and broaden the clinical application of these agents in cardiometabolic care.<\/jats:p>","DOI":"10.3390\/ijms26146777","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:01:05Z","timestamp":1752591665000},"page":"6777","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8658-4356","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Kr\u00f3l","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0756-6483","authenticated-orcid":false,"given":"Patrycja","family":"Kupnicka","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3477-3430","authenticated-orcid":false,"given":"Justyna","family":"\u017bychowska","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2766-7783","authenticated-orcid":false,"given":"Patrycja","family":"Kapczuk","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2974-1908","authenticated-orcid":false,"given":"Izabela","family":"Szu\u0107ko-Kociuba","sequence":"additional","affiliation":[{"name":"Institute of Biology, University of Szczecin, 13 W\u0105ska, 71-415 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9827-7114","authenticated-orcid":false,"given":"Eryk","family":"Prajwos","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4497-4395","authenticated-orcid":false,"given":"Dariusz","family":"Chlubek","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.jacc.2019.10.009","article-title":"The Global Burden of Cardiovascular Diseases and Risk Factors","volume":"74","author":"Mensah","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990\u20132019: A Systematic Analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart Disease and Stroke Statistics\u20142018 Update: A Report From the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide Cardiovascular Event Risk Assessment: A Pre-Specified Meta-Analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"E347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bosco, E., Hsueh, L., McConeghy, K.W., Gravenstein, S., and Saade, E. (2021). Major Adverse Cardiovascular Event Definitions Used in Observational Analysis of Administrative Databases: A Systematic Review. BMC Med. Res. Methodol., 21.","DOI":"10.1186\/s12874-021-01440-5"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Dubois-Deruy, E., Peugnet, V., Turkieh, A., and Pinet, F. (2020). Oxidative Stress in Cardiovascular Diseases. Antioxidants, 9.","DOI":"10.3390\/antiox9090864"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e002555","DOI":"10.1161\/JAHA.115.002555","article-title":"Mitochondrial Reactive Oxygen Species Mediate Cardiac Structural, Functional, and Mitochondrial Consequences of Diet-Induced Metabolic Heart Disease","volume":"5","author":"Sverdlov","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ramos-Mondrag\u00f3n, R., Lozhkin, A., Vendrov, A.E., Runge, M.S., Isom, L.L., and Madamanchi, N.R. (2023). NADPH Oxidases and Oxidative Stress in the Pathogenesis of Atrial Fibrillation. Antioxidants, 12.","DOI":"10.3390\/antiox12101833"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Senoner, T., and Dichtl, W. (2019). Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target?. Nutrients, 11.","DOI":"10.3390\/nu11092090"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/152786","article-title":"LOX-1, OxLDL, and Atherosclerosis","volume":"2013","author":"Pirillo","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41569-021-00607-3","article-title":"Epidemiology of Cardiovascular Disease in Europe","volume":"19","author":"Townsend","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1055\/s-0041-1729925","article-title":"Primary and Secondary Prevention of CAD: A Review","volume":"31","author":"Short","year":"2022","journal-title":"Int. J. Angiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 Receptor Expression Within the Human Heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like Peptide I Stimulates Insulin Gene Expression and Increases Cyclic AMP Levels in a Rat Islet Cell Line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","article-title":"Secretion of Glucagon-like Peptide-1 in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analyses of Clinical Studies","volume":"56","author":"Calanna","year":"2013","journal-title":"Diabetologia"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lastya, A., Saraswati, M.R., and Suastika, K. (2014). The Low Level of Glucagon-like Peptide-1 (Glp-1) Is a Risk Factor of Type 2 Diabetes Mellitus. BMC Res. Notes, 7.","DOI":"10.1186\/1756-0500-7-849"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.pcd.2023.07.006","article-title":"Weight Loss and Side-Effects of Liraglutide and Lixisenatide in Obesity and Type 2 Diabetes Mellitus","volume":"17","author":"Lee","year":"2023","journal-title":"Prim. Care Diabetes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for Adults with Overweight and Obesity: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101641","DOI":"10.1016\/j.molmet.2022.101641","article-title":"Glucagon-like Peptide-1 Receptor Tie2+ Cells Are Essential for the Cardioprotective Actions of Liraglutide in Mice with Experimental Myocardial Infarction","volume":"66","author":"McLean","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/db13-1440","article-title":"Identification and Characterization of GLP-1 Receptor\u2013Expressing Cells Using a New Transgenic Mouse Model","volume":"63","author":"Richards","year":"2014","journal-title":"Diabetes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cvr\/cvae120","article-title":"Glucagon-like Peptide-1 Increases Heart Rate by a Direct Action on the Sinus Node","volume":"120","author":"Lubberding","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor\u2013Dependent and \u2013Independent Pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed with Extensively Validated Monoclonal Antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bph.15462","article-title":"Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Their Cardiovascular Benefits\u2014The Role of the GLP-1 Receptor","volume":"179","author":"Keppeler","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00395-021-00873-9","article-title":"Glucagon-like Peptide-1 (GLP-1) Receptor Activation Dilates Cerebral Arterioles, Increases Cerebral Blood Flow, and Mediates Remote (Pre)Conditioning Neuroprotection against Ischaemic Stroke","volume":"116","author":"Nizari","year":"2021","journal-title":"Basic Res. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1210\/er.2016-1078","article-title":"Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance","volume":"37","author":"Pujadas","year":"2016","journal-title":"Endocr. Rev."},{"key":"ref_29","unstructured":"(2025, January 10). 2025 Broad Institute of MIT and Harvard Gene Symbol Gencode ID Entrez Gene ID Location Gene Description GLP1R ENSG00000112164.6 2740 chr6:39048781-39091303:+ Glucagon Like Peptide 1 Receptor [Source:HGNC Symbol;Acc:HGNC:4324]. Available online: https:\/\/gtexportal.org\/home\/gene\/GLP1R#geneExpression."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","article-title":"Circulation and Degradation of GIP and GLP-1","volume":"36","author":"Deacon","year":"2004","journal-title":"Horm. Metab. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes\u2014State-of-the-Art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kim, N.-H., Yu, T., and Lee, D.H. (2014). The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/368703"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Deacon, C.F. (2019). Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00080"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc07-0228","article-title":"Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes: Preclinical Biology and Mechanisms of Action","volume":"30","author":"Drucker","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","article-title":"Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes: A Comparative Review","volume":"13","author":"Deacon","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.bcp.2011.11.028","article-title":"DPP-4 Inhibitors in the Treatment of Type 2 Diabetes","volume":"83","author":"Duez","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diabet.2011.11.001","article-title":"DPP-4 Inhibitors in the Management of Type 2 Diabetes: A Critical Review of Head-to-Head Trials","volume":"38","author":"Scheen","year":"2012","journal-title":"Diabetes Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","article-title":"Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis","volume":"124","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e083550","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 Receptor Agonists in Early Pregnancy and Reproductive Safety: A Multicentre, Observational, Prospective Cohort Study Based on the Databases of Six Teratology Information Services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/17460441.2013.741580","article-title":"Discovery and Development of Exenatide: The First Antidiabetic Agent to Leverage the Multiple Benefits of the Incretin Hormone, GLP-1","volume":"8","author":"Parkes","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.2337\/db16-1009","article-title":"Glucagon-Like Peptide 1 Protects Pancreatic \u03b2-Cells From Death by Increasing Autophagic Flux and Restoring Lysosomal Function","volume":"66","author":"Zummo","year":"2017","journal-title":"Diabetes"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00125-024-06348-5","article-title":"Once-Weekly IcoSema versus Once-Weekly Semaglutide in Adults with Type 2 Diabetes: The COMBINE 2 Randomised Clinical Trial","volume":"68","author":"Lingvay","year":"2025","journal-title":"Diabetologia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1515\/jbcpp-2024-0157","article-title":"IcoSema\u2019s Leap Forward: New Data from COMBINE 3 Paves the Way","volume":"35","author":"Seetharaman","year":"2024","journal-title":"J. Basic. Clin. Physiol. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc23-1287","article-title":"Efficacy and Safety of Mazdutide in Chinese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A Phase 2 Randomised Controlled Trial of Mazdutide in Chinese Overweight Adults or Adults with Obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2\u00b74 Mg with Once-Weekly Semaglutide 2\u00b74 Mg in Type 2 Diabetes: A Multicentre, Randomised, Double-Blind, Active-Controlled, Phase 2 Trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative Effectiveness of GLP-1 Receptor Agonists on Glycaemic Control, Body Weight, and Lipid Profile for Type 2 Diabetes: Systematic Review and Network Meta-Analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 Receptor Dual Agonist Survodutide for Obesity: A Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Trial","volume":"12","author":"Steen","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lin, D., Xiao, H., Yang, K., Li, J., Ye, S., Liu, Y., Jing, S., Lin, Y., Yang, Y., and Huang, L. (2024). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TG103 Injection in Participants Who Are Overweight or Obese: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase 1b Study. BMC Med., 22.","DOI":"10.1186\/s12916-024-03394-z"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of Exenatide (Synthetic Exendin-4): A Potential Therapeutic for Improved Glycemic Control of Type 2 Diabetes","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul. Pept."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ahn, Y.-J., Shin, H.-J., Jeong, E.-A., An, H.-S., Lee, J.-Y., Jang, H.-M., Kim, K.-E., Lee, J., Shin, M.-C., and Roh, G.-S. (2021). Exendin-4 Pretreatment Attenuates Kainic Acid-Induced Hippocampal Neuronal Death. Cells, 10.","DOI":"10.3390\/cells10102527"},{"key":"ref_53","first-page":"237","article-title":"Exendin-4 as a Versatile Therapeutic Agent for the Amelioration of Diabetic Changes","volume":"12","author":"Rajabi","year":"2021","journal-title":"Adv. Pharm. Bull."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4103\/2230-8210.111625","article-title":"Glucagon-like Peptide-1 Analogues: An Overview","volume":"17","author":"Gupta","year":"2013","journal-title":"Indian. J. Endocrinol. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"G\u00f3rriz, J.L., Soler, M.J., Navarro-Gonz\u00e1lez, J.F., Garc\u00eda-Carro, C., Puchades, M.J., D\u2019Marco, L., Mart\u00ednez Castelao, A., Fern\u00e1ndez-Fern\u00e1ndez, B., Ortiz, A., and G\u00f3rriz-Zambrano, C. (2020). GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. J. Clin. Med., 9.","DOI":"10.3390\/jcm9040947"},{"key":"ref_56","unstructured":"Kasina, S.V.S.K., and Baradhi, K.M. (2025). Dipeptidyl Peptidase IV (DPP IV) Inhibitors. StatPearls, StatPearls Publishing."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1331\/JAPhA.2009.09078","article-title":"Differential Chemistry (Structure), Mechanism of Action, and Pharmacology of GLP-1 Receptor Agonists and DPP-4 Inhibitors","volume":"49","author":"Neumiller","year":"2009","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1463-1326.2012.01603.x","article-title":"Glycaemic Efficacy of Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors as Add-on Therapy to Metformin in Subjects with Type 2 Diabetes-a Review and Meta Analysis","volume":"14","author":"Deacon","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/dom.13137","article-title":"Efficacy of Glucagon-like Peptide-1 Receptor Agonists Compared to Dipeptidyl Peptidase-4 Inhibitors for the Management of Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials","volume":"20","author":"Tran","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3810\/pgm.2011.11.2508","article-title":"The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors","volume":"123","author":"Morales","year":"2011","journal-title":"Postgrad. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.metabol.2019.06.016","article-title":"Incretin-Based Medications (GLP-1 Receptor Agonists, DPP-4 Inhibitors) as a Means to Avoid Hypoglycaemic Episodes","volume":"99","author":"Farngren","year":"2019","journal-title":"Metabolism"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ando.2012.06.002","article-title":"GLP-1 Receptor Agonists or DPP-4 Inhibitors: How to Guide the Clinician?","volume":"74","author":"Scheen","year":"2013","journal-title":"Ann. Endocrinol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gilbert, M.P., and Pratley, R.E. (2020). GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00178"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","article-title":"Network Meta-Analysis on the Effects of Finerenone versus SGLT2 Inhibitors and GLP-1 Receptor Agonists on Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s00125-021-05529-w","article-title":"The Efficacy and Safety of Novel Classes of Glucose-Lowering Drugs for Cardiovascular Outcomes: A Network Meta-Analysis of Randomised Clinical Trials","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13300-017-0329-5","article-title":"Factors That May Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus","volume":"9","author":"Evans","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/dom.12548","article-title":"Cardiovascular and Heart Failure Safety Profile of Vildagliptin: A Meta-analysis of 17 000 Patients","volume":"17","author":"McInnes","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12933-023-01877-6","article-title":"Characteristics Predicting the Efficacy of SGLT-2 Inhibitors versus GLP-1 Receptor Agonists on Major Adverse Cardiovascular Events in Type 2 Diabetes Mellitus: A Meta-Analysis Study","volume":"22","author":"Sohn","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-022-01572-y","article-title":"Effectiveness and Safety of GLP-1 Receptor Agonists versus SGLT-2 Inhibitors in Type 2 Diabetes: An Italian Cohort Study","volume":"21","author":"Baviera","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care, 48, S207\u2013S238.","DOI":"10.2337\/dc25-S010"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1111\/dom.15219","article-title":"Effects of Once-weekly Glucagon-like Peptide-1 Receptor Agonists on Type 2 Diabetes Mellitus Complicated with Coronary Artery Disease: Potential Role of the Renin-angiotensin System","volume":"25","author":"Kan","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1111\/dom.15185","article-title":"All-cause Mortality and Cardiovascular Outcomes with SODIUM-GLUCOSE Co-transporter 2 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists and with Combination Therapy in People with Type 2 Diabetes","volume":"25","author":"Riley","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","article-title":"Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals with Obesity and without Diabetes: A Systematic Review and Meta-Analysis","volume":"30","author":"Ansari","year":"2024","journal-title":"Endocr. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40256-024-00647-3","article-title":"Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials","volume":"24","author":"Balieiro","year":"2024","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.atherosclerosis.2020.06.003","article-title":"Tissue Factor in Atherosclerosis and Atherothrombosis","volume":"307","author":"Grover","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.ehj.2004.03.011","article-title":"Atherothrombosis: A Widespread Disease with Unpredictable and Life-Threatening Consequences","volume":"25","author":"Fuster","year":"2004","journal-title":"Eur. Heart J."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Jebari-Benslaiman, S., Galicia-Garc\u00eda, U., Larrea-Sebal, A., Olaetxea, J.R., Alloza, I., Vandenbroeck, K., Benito-Vicente, A., and Mart\u00edn, C. (2022). Pathophysiology of Atherosclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063346"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Kahal, H., Aburima, A., Ungvari, T., Rigby, A.S., Coady, A.M., Vince, R.V., Ajjan, R.A., Kilpatrick, E.S., Naseem, K.M., and Atkin, S.L. (2015). The Effects of Treatment with Liraglutide on Atherothrombotic Risk in Obese Young Women with Polycystic Ovary Syndrome and Controls. BMC Endocr. Disord., 15.","DOI":"10.1186\/s12902-015-0005-6"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Luna-Marco, C., De Mara\u00f1on, A.M., Hermo-Argibay, A., Rodriguez-Hernandez, Y., Hermenejildo, J., Fernandez-Reyes, M., Apostolova, N., Vila, J., Sola, E., and Morillas, C. (2023). Effects of GLP-1 Receptor Agonists on Mitochondrial Function, Inflammatory Markers and Leukocyte-Endothelium Interactions in Type 2 Diabetes. Redox Biol., 66.","DOI":"10.1016\/j.redox.2023.102849"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice with Experimental Arterial Hypertension","volume":"40","author":"Frenis","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE\u2212\/\u2212 and LDLr\u2212\/\u2212 Mice by a Mechanism That Includes Inflammatory Pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41569-022-00737-2","article-title":"Gut-Derived Low-Grade Endotoxaemia, Atherothrombosis and Cardiovascular Disease","volume":"20","author":"Violi","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/gut.2008.165886","article-title":"Changes in Gut Microbiota Control Inflammation in Obese Mice through a Mechanism Involving GLP-2-Driven Improvement of Gut Permeability","volume":"58","author":"Cani","year":"2009","journal-title":"Gut"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.biochi.2015.06.020","article-title":"Metabolic Endotoxemia with Obesity: Is It Real and Is It Relevant?","volume":"124","author":"Boutagy","year":"2016","journal-title":"Biochimie"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"H2042","DOI":"10.1152\/ajpheart.00467.2015","article-title":"Lipopolysaccharide Modulates Neutrophil Recruitment and Macrophage Polarization on Lymphatic Vessels and Impairs Lymphatic Function in Rat Mesentery","volume":"309","author":"Chakraborty","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Athapaththu, A.M.G.K., Lee, K.T., Kavinda, M.H.D., Lee, S., Kang, S., Lee, M.-H., Kang, C.-H., Choi, Y.H., and Kim, G.-Y. (2022). Pinostrobin Ameliorates Lipopolysaccharide (LPS)-Induced Inflammation and Endotoxemia by Inhibiting LPS Binding to the TLR4\/MD2 Complex. Biomed. Pharmacother., 156.","DOI":"10.1016\/j.biopha.2022.113874"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00395-015-0465-x","article-title":"Gliptin and GLP-1 Analog Treatment Improves Survival and Vascular Inflammation\/Dysfunction in Animals with Lipopolysaccharide-induced Endotoxemia","volume":"110","author":"Steven","year":"2015","journal-title":"Basic Res. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2218684","DOI":"10.1080\/13510002.2023.2218684","article-title":"Liraglutide Ameliorates Oxidized LDL-Induced Endothelial Dysfunction by GLP-1R-Dependent Downregulation of LOX-1-Mediated Oxidative Stress and Inflammation","volume":"28","author":"Ying","year":"2023","journal-title":"Redox Rep."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Terasaki, M., Yashima, H., Mori, Y., Saito, T., Matsui, T., Hiromura, M., Kushima, H., Osaka, N., Ohara, M., and Fukui, T. (2020). A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134811"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e165933","DOI":"10.1172\/JCI165933","article-title":"DPP4 Inhibition Impairs Senohemostasis to Improve Plaque Stability in Atherosclerotic Mice","volume":"133","author":"Herman","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.114.03618","article-title":"Matrix Metalloproteinases Promote Arterial Remodeling in Aging, Hypertension, and Atherosclerosis","volume":"65","author":"Wang","year":"2015","journal-title":"Hypertension"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e12317","DOI":"10.1111\/1755-5922.12317","article-title":"Exenatide Exhibits Anti-inflammatory Properties and Modulates Endothelial Response to Tumor Necrosis Factor A-mediated Activation","volume":"36","author":"Garczorz","year":"2018","journal-title":"Cardiovasc. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"714653","DOI":"10.1155\/2013\/714653","article-title":"The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts","volume":"2013","author":"Maiolino","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejphar.2019.02.014","article-title":"The Effect of Exenatide (a GLP-1 Analog) and Sitagliptin (a DPP-4 Inhibitor) on Plasma Platelet-Activating Factor Acetylhydrolase (PAF-AH) Activity and Concentration in Normal and Fructose-Fed Rats","volume":"850","author":"Warpas","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Pignatelli, P., Baratta, F., Buzzetti, R., D\u2019Amico, A., Castellani, V., Bartimoccia, S., Siena, A., D\u2019Onofrio, L., Maddaloni, E., and Pingitore, A. (2022). The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study. Antioxidants, 11.","DOI":"10.3390\/antiox11101878"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/ATVBAHA.110.206425","article-title":"Glucagon-like Peptide 1 Prevents Reactive Oxygen Species-Induced Endothelial Cell Senescence through the Activation of Protein Kinase A","volume":"30","author":"Oeseburg","year":"2010","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.2337\/dc12-2469","article-title":"Glucagon-like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes","volume":"36","author":"Ceriello","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.120.047965","article-title":"Risk of Cardiovascular Outcomes in Patients with Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy","volume":"143","author":"Dave","year":"2021","journal-title":"Circulation"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"102382","DOI":"10.1016\/j.dsx.2021.102382","article-title":"Cardiovascular and Mortality Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Meta-Analysis with the FREEDOM Cardiovascular Outcomes Trial","volume":"16","author":"Lee","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.7150\/ijbs.27774","article-title":"GLP-1 Treatment Protects Endothelial Cells from Oxidative Stress-Induced Autophagy and Endothelial Dysfunction","volume":"14","author":"Cai","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s11010-023-04784-2","article-title":"Semaglutide Ameliorates Obesity-Induced Cardiac Inflammation and Oxidative Stress Mediated via Reduction of Neutrophil Cxcl2, S100a8, and S100a9 Expression","volume":"479","author":"Pan","year":"2024","journal-title":"Mol. Cell Biochem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00210-015-1124-3","article-title":"Exenatide (a GLP-1 Agonist) Improves the Antioxidative Potential of in Vitro Cultured Human Monocytes\/Macrophages","volume":"388","author":"Machnik","year":"2015","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"10245","DOI":"10.1039\/C9RA09959J","article-title":"The Protective Effects of GLP-1 Receptor Agonist Lixisenatide on Oxygen-Glucose Deprivation\/Reperfusion (OGD\/R)-Induced Deregulation of Endothelial Tube Formation","volume":"10","author":"Xiao","year":"2020","journal-title":"RSC Adv."},{"key":"ref_105","first-page":"A18087","article-title":"Abstract 18087: GLP-1 Receptor Agonist Exenatide Attenuates Endothelial Dysfunction by Reducing Oxidative Stress in Hyperhomocysteinemia via AMPK\/eNOS Pathway","volume":"136","author":"Cheng","year":"2017","journal-title":"Circulation"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1479164111404257","article-title":"A GLP-1 Receptor Agonist Liraglutide Inhibits Endothelial Cell Dysfunction and Vascular Adhesion Molecule Expression in an ApoE-\/- Mouse Model","volume":"8","author":"Gaspari","year":"2011","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"H1829","DOI":"10.1152\/ajpheart.00230.2009","article-title":"eNOS Uncoupling and Endothelial Dysfunction in Aged Vessels","volume":"297","author":"Yang","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2337\/db12-1025","article-title":"Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP\/PKA\/Rho-Dependent Mechanism","volume":"62","author":"Wang","year":"2013","journal-title":"Diabetes"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2337\/db22-0745","article-title":"Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-Induced Obesity","volume":"72","author":"Liu","year":"2023","journal-title":"Diabetes"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/01.ATV.0000168896.64927.bb","article-title":"Vascular Consequences of Endothelial Nitric Oxide Synthase Uncoupling for the Activity and Expression of the Soluble Guanylyl Cyclase and the cGMP-Dependent Protein Kinase","volume":"25","author":"Daiber","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like Peptide 1 Analogue Therapy Directly Modulates Innate Immune-Mediated Inflammation in Individuals with Type 2 Diabetes Mellitus","volume":"57","author":"Hogan","year":"2014","journal-title":"Diabetologia"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Dabravolski, S.A., Sukhorukov, V.N., Kalmykov, V.A., Grechko, A.V., Shakhpazyan, N.K., and Orekhov, A.N. (2022). The Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020254"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-015-0852-y","article-title":"Effects of Glucagon-like Peptide-1 on Advanced Glycation Endproduct-Induced Aortic Endothelial Dysfunction in Streptozotocin-Induced Diabetic Rats: Possible Roles of Rho Kinase- and AMP Kinase-Mediated Nuclear Factor \u03baB Signaling Pathways","volume":"53","author":"Tang","year":"2016","journal-title":"Endocrine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"H491","DOI":"10.1152\/ajpheart.00464.2008","article-title":"AGE\/RAGE Produces Endothelial Dysfunction in Coronary Arterioles in Type 2 Diabetic Mice","volume":"295","author":"Gao","year":"2008","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Chen, Z., Yu, J., Fu, M., Dong, R., Yang, Y., Luo, J., Hu, S., Li, W., Xu, X., and Tu, L. (2020). Dipeptidyl Peptidase-4 Inhibition Improves Endothelial Senescence by Activating AMPK\/SIRT1\/Nrf2 Signaling Pathway. Biochem. Pharmacol., 177.","DOI":"10.1016\/j.bcp.2020.113951"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Guo, C., Huang, T., Chen, A., Chen, X., Wang, L., Shen, F., and Gu, X. (2016). Glucagon-like Peptide 1 Improves Insulin Resistance in Vitro through Anti-Inflammation of Macrophages. Braz. J. Med. Biol. Res., 49.","DOI":"10.1590\/1414-431x20165826"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1111\/bcp.14063","article-title":"Liraglutide Treatment Reduced Interleukin-6 in Adults with Type 1 Diabetes but Did Not Improve Established Autonomic or Polyneuropathy","volume":"85","author":"Brock","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/dom.12884","article-title":"Effects of Liraglutide on Cardiovascular Risk Biomarkers in Patients with Type 2 Diabetes and Albuminuria: A Sub-analysis of a Randomized, Placebo-controlled, Double-blind, Crossover Trial","volume":"19","author":"Persson","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide Exerts a Potent Antiinflammatory Effect","volume":"97","author":"Chaudhuri","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1210\/jc.2012-1544","article-title":"Sitagliptin Exerts an Antinflammatory Action","volume":"97","author":"Makdissi","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12933-015-0177-4","article-title":"Liraglutide Attenuates High Glucose-Induced Abnormal Cell Migration, Proliferation, and Apoptosis of Vascular Smooth Muscle Cells by Activating the GLP-1 Receptor, and Inhibiting ERK1\/2 and PI3K\/Akt Signaling Pathways","volume":"14","author":"Shi","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Gilbert, C.J., Longenecker, J.Z., and Accornero, F. (2021). ERK1\/2: An Integrator of Signals That Alters Cardiac Homeostasis and Growth. Biology, 10.","DOI":"10.3390\/biology10040346"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2012.11.057","article-title":"Exendin-4, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Neointimal Hyperplasia after Vascular Injury","volume":"699","author":"Hirata","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molimm.2019.09.021","article-title":"Glucagon-like Peptide-1 Receptor Agonist Dulaglutide Prevents Ox-LDL-Induced Adhesion of Monocytes to Human Endothelial Cells: An Implication in the Treatment of Atherosclerosis","volume":"116","author":"Chang","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/00015385.2022.2087839","article-title":"Meta-Analysis of Cardiovascular Outcome Trials Assessing the Impact of Glucagon-like Peptide-1 Receptor Agonists on Major Cardiac Arrhythmias","volume":"78","author":"Boulmpou","year":"2023","journal-title":"Acta Cardiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12933-022-01549-x","article-title":"The Risk of Incident Atrial Fibrillation in Patients with Type 2 Diabetes Treated with Sodium Glucose Cotransporter-2 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors: A Nationwide Cohort Study","volume":"21","author":"Chan","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12933-023-01772-0","article-title":"Risks of Stroke, Its Subtypes and Atrial Fibrillation Associated with Glucagon-like Peptide 1 Receptor Agonists versus Sodium-Glucose Cotransporter 2 Inhibitors: A Real-World Population-Based Cohort Study in Hong Kong","volume":"22","author":"Lui","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/9993229","article-title":"Effects of Liraglutide on Left Ventricular Function: A Meta-Analysis of Randomized, Placebo-Controlled Trials","volume":"2021","author":"Zhong","year":"2021","journal-title":"Int. J. Endocrinol."},{"key":"ref_130","first-page":"e0265","article-title":"Can Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Help in Mitigating the Risk of Atrial Fibrillation in Patients with Diabetes?","volume":"11","author":"Thotamgari","year":"2022","journal-title":"Cardiovasc. Endocrinol. Metab."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbrc.2022.07.034","article-title":"Single-Cell Transcriptome Reveals Effects of Semaglutide on Non-Cardiomyocytes of Obese Mice","volume":"622","author":"Pan","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10561-022-10021-9","article-title":"Liraglutide Inhibits AngII-Induced Cardiac Fibroblast Proliferation and ECM Deposition through Regulating miR-21\/PTEN\/PI3K Pathway","volume":"24","author":"Wang","year":"2023","journal-title":"Cell Tissue Bank."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Surina, S., Fontanella, R.A., Scisciola, L., Marfella, R., Paolisso, G., and Barbieri, M. (2021). miR-21 in Human Cardiomyopathies. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.767064"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"W\u00f3jcicka, G., Pradiuch, A., Fornal, E., Stachniuk, A., Korolczuk, A., Marzec-Kotarska, B., Nikolaichuk, H., Czechowska, G., Kozub, A., and Trzpil, A. (2023). The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome. Biochem. Pharmacol., 214.","DOI":"10.1016\/j.bcp.2023.115637"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, Incidence and Lifetime Risk of Atrial Fibrillation: The Rotterdam Study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur. Heart J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/01.CIR.0000083722.42033.0A","article-title":"Increasing Trends in Hospitalization for Atrial Fibrillation in the United States, 1985 Through 1999: Implications for Primary Prevention","volume":"108","author":"Wattigney","year":"2003","journal-title":"Circulation"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1582-4934.2008.00219.x","article-title":"Atrial Extracellular Matrix Remodelling in Patients with Atrial Fibrillation","volume":"12","author":"Polyakova","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1747493019897870","article-title":"Global Epidemiology of Atrial Fibrillation: An Increasing Epidemic and Public Health Challenge","volume":"16","author":"Lippi","year":"2021","journal-title":"Int. J. Stroke"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/STROKEAHA.120.029048","article-title":"Ischemic Stroke in Patients with Sinus Node Disease, Atrial Fibrillation, and Other Cardiac Conditions","volume":"51","author":"Bodin","year":"2020","journal-title":"Stroke"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10741-022-10238-6","article-title":"Diabetes Leading to Heart Failure and Heart Failure Leading to Diabetes: Epidemiological and Clinical Evidence","volume":"28","author":"Palazzuoli","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_141","first-page":"e984","article-title":"Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association","volume":"143","author":"Poirier","year":"2021","journal-title":"Circulation"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40885-019-0132-x","article-title":"Blood Pressure and Heart Failure","volume":"26","author":"Oh","year":"2020","journal-title":"Clin. Hypertens."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Kreiner, F.F., Hovingh, G.K.K., and Von Scholten, B.J. (2022). The Potential of Glucagon-like Peptide-1 Receptor Agonists in Heart Failure. Front. Physiol., 13.","DOI":"10.3389\/fphys.2022.983961"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/clinem\/dgad398","article-title":"Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure","volume":"109","author":"Ferreira","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijcard.2017.03.163","article-title":"Effects of Glucagon-like Peptide-1 Receptor Agonists on Mortality and Cardiovascular Events: A Comprehensive Meta-Analysis of Randomized Controlled Trials","volume":"240","author":"Monami","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart Failure and Mortality Outcomes in Patients with Type 2 Diabetes Taking Alogliptin versus Placebo in EXAMINE: A Multicentre, Randomised, Double-Blind Trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_151","unstructured":"(2025, January 10). The U.S. Food and Drug Administration FDA Drug Safety Communication: FDA Adds Warnings about Heart Failure Risk to Labels of Type 2 Diabetes Medicines Containing Saxagliptin and Alogliptin, Available online: https:\/\/www.fda.gov\/about-fda\/fda-organization."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/dom.12951","article-title":"Cardiovascular Safety of Vildagliptin in Patients with Type 2 Diabetes: A European Multi-database, Non-interventional Post-authorization Safety Study","volume":"19","author":"Williams","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients with Type 2 Diabetes: The CAROLINA Randomized Clinical Trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared with Conventional Care in Patients with Type 2 Diabetes and Albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e15157","DOI":"10.1111\/dme.15157","article-title":"Effects of DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT-2 Inhibitors and Sulphonylureas on Mortality, Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Network Meta-analyses-driven Approach","volume":"40","author":"Christensen","year":"2023","journal-title":"Diabet. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2337\/dc10-2421","article-title":"Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes","volume":"34","author":"Netea","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"Effects of Vildagliptin on Ventricular Function in Patients with Type 2 Diabetes Mellitus and Heart Failure","volume":"6","author":"McMurray","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl Peptidase-IV Inhibitor Use Associated with Increased Risk of ACE Inhibitor-Associated Angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjcard.2021.11.013","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization","volume":"165","author":"Lyu","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","article-title":"The Effect of DPP-4 Inhibitors, GLP-1 Receptor Agonists and SGLT-2 Inhibitors on Cardiorenal Outcomes: A Network Meta-Analysis of 23 CVOTs","volume":"21","author":"Giugliano","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.2337\/dc23-0671","article-title":"Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes","volume":"46","author":"Kutz","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-023-01743-5","article-title":"The Real-World Safety Profile of Sodium-Glucose Co-Transporter-2 Inhibitors among Older Adults (\u226575 Years): A Retrospective, Pharmacovigilance Study","volume":"22","author":"Goldman","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2023.01.049","article-title":"Semaglutide Inhibits Ischemia\/Reperfusion-Induced Cardiomyocyte Apoptosis through Activating PKG\/PKC\u03b5\/ERK1\/2 Pathway","volume":"647","author":"Zhu","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1210\/endo.132.5.8477647","article-title":"Mechanisms of Atrial and Brain Natriuretic Peptide Release from Rat Ventricular Myocardium: Effect of Stretching","volume":"132","author":"Kinnunen","year":"1993","journal-title":"Endocrinology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"107863","DOI":"10.1016\/j.pharmthera.2021.107863","article-title":"The Natriuretic Peptide System in Heart Failure: Diagnostic and Therapeutic Implications","volume":"227","author":"Kuwahara","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e230176","DOI":"10.1530\/EC-23-0176","article-title":"Effects of Liraglutide on ANP Secretion and Cardiac Dynamics","volume":"12","author":"Luo","year":"2023","journal-title":"Endocr. Connect."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/dom.14135","article-title":"The Impact of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes","volume":"22","author":"Nielsen","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-017-0646-z","article-title":"Effects of 6-Month Treatment with the Glucagon like Peptide-1 Analogue Liraglutide on Arterial Stiffness, Left Ventricular Myocardial Deformation and Oxidative Stress in Subjects with Newly Diagnosed Type 2 Diabetes","volume":"17","author":"Lambadiari","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/1755-5922.12005","article-title":"DPP-4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes","volume":"31","author":"Connelly","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1475-2840-10-85","article-title":"Early and Late Effects of the DPP-4 Inhibitor Vildagliptin in a Rat Model of Post-Myocardial Infarction Heart Failure","volume":"10","author":"Yin","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijcard.2015.03.433","article-title":"The Effects and Safety of Vildagliptin on Cardiac Function after Acute Myocardial Infarction","volume":"188","author":"Nishikido","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"215re3","DOI":"10.1126\/scitranslmed.3007328","article-title":"Metabolic Rates of ATP Transfer Through Creatine Kinase (CK Flux) Predict Clinical Heart Failure Events and Death","volume":"5","author":"Bottomley","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e026728","DOI":"10.1161\/JAHA.122.026728","article-title":"Long-Term Activation of Glucagon-like Peptide-1 Receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes","volume":"11","author":"Xie","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/sj.embor.7401077","article-title":"The Phosphorylation State of Drp1 Determines Cell Fate","volume":"8","author":"Slack","year":"2007","journal-title":"EMBO Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1194\/jlr.RA119000141","article-title":"Lysophosphatidylcholine-Induced Mitochondrial Fission Contributes to Collagen Production in Human Cardiac Fibroblasts","volume":"60","author":"Tseng","year":"2019","journal-title":"J. Lipid Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.yjmcc.2018.07.004","article-title":"Mitochondrial Fission Protein, Dynamin-Related Protein 1, Contributes to the Promotion of Hypertensive Cardiac Hypertrophy and Fibrosis in Dahl-Salt Sensitive Rats","volume":"121","author":"Hasan","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13105-022-00939-9","article-title":"Liraglutide Provides Cardioprotection through the Recovery of Mitochondrial Dysfunction and Oxidative Stress in Aging Hearts","volume":"79","author":"Durak","year":"2023","journal-title":"J. Physiol. Biochem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e027163","DOI":"10.1161\/JAHA.122.027163","article-title":"Cardioprotective Actions of a Glucagon-like Peptide-1 Receptor Agonist on Hearts Donated After Circulatory Death","volume":"12","author":"Kadowaki","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_181","unstructured":"(2025, January 10). Centers for Disease Control and Prevention National Center for Health Statistics Mortality Data on CDC WONDER, Available online: https:\/\/wonder.cdc.gov\/mcd.html."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Sharifi-Rad, J., Rodrigues, C.F., Sharopov, F., Docea, A.O., Can Karaca, A., Sharifi-Rad, M., Kahveci Kar\u0131ncaoglu, D., G\u00fclseren, G., \u015eenol, E., and Demircan, E. (2020). Diet, Lifestyle and Cardiovascular Diseases: Linking Pathophysiology to Cardioprotective Effects of Natural Bioactive Compounds. Int. J. Env. Res. Public. Health, 17.","DOI":"10.3390\/ijerph17072326"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like Peptide-1 Receptor: Mechanisms and Advances in Therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Sig Transduct. Target. Ther."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"n71","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_185","first-page":"ED000142","article-title":"Updated Guidance for Trusted Systematic Reviews: A New Edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6777\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:10:06Z","timestamp":1760033406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":185,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26146777"],"URL":"https:\/\/doi.org\/10.3390\/ijms26146777","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}